United States v. Blaszczak

947 F.3d 19
CourtCourt of Appeals for the Second Circuit
DecidedDecember 30, 2019
Docket18-2811 (L)
StatusPublished
Cited by6 cases

This text of 947 F.3d 19 (United States v. Blaszczak) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Blaszczak, 947 F.3d 19 (2d Cir. 2019).

Opinion

18-2811 (L) United States v. Blaszczak

United States Court of Appeals for the Second Circuit

AUGUST TERM 2019

Docket Nos. 18-2811, 18-2825, 18-2867, 18-2878

UNITED STATES OF AMERICA,

Appellee,

v.

DAVID BLASZCZAK, THEODORE HUBER, ROBERT OLAN, CHRISTOPHER WORRALL,

Defendants-Appellants.

ARGUED: NOVEMBER 21, 2019

DECIDED: DECEMBER 30, 2019

Before: KEARSE, DRONEY, AND SULLIVAN, Circuit Judges.

Defendants David Blaszczak, Theodore Huber, Robert Olan, and Christopher Worrall appeal from judgments of conviction following a jury trial before the United States District Court for the Southern District of New York (Kaplan, Judge) for wire fraud, Title 18 securities fraud, conversion of U.S. property, and conspiracy, arising from the misappropriation of confidential information from the Centers for Medicare & Medicaid Services. On appeal, Defendants argue that the evidence at trial was insufficient in various respects, the district court committed instructional and evidentiary errors, and there was prejudicial misjoinder for two counts in which Blaszczak alone was charged. We reject each of these challenges. In doing so, we hold, inter alia, that (1) confidential government information may constitute “property” for purposes of the wire fraud and Title 18 securities fraud statutes, and (2) the “personal-benefit” test announced in Dirks v. SEC, 463 U.S. 646 (1983), does not apply to those Title 18 fraud statutes. Because we also discern no prejudicial error with respect to the other issues presented on appeal, we AFFIRM the judgments of the district court.

Judge Kearse dissents in a separate opinion.

SARAH K. EDDY, Assistant United States Attorney (Ian McGinley, Joshua A. Naftalis, Won S. Shin, Assistant United States Attorneys, on the brief), for Geoffrey S. Berman, United States Attorney for the Southern District of New York, New York, NY, for Appellee United States of America. DONALD B. VERILLI, JR. (Elaine J. Goldenberg, Jonathan S. Meltzer, on the brief), Munger, Tolles & Olson LLP, Washington, D.C., David Esseks, Eugene Ingoglia, Rachel Agress, Alexander Bussey, on the brief, Allen & Overy LLP, New York, NY, for Appellant Robert Olan. ALEXANDRA A.E. SHAPIRO (Eric S. Onley, on the brief), Shapiro Arato Bach LLP, New York, NY, Dani R. James, on the brief,

2 Kramer Levin Naftalis & Frankel, LLP, New York, NY, for Appellant Theodore Huber. COLLEEN P. CASSIDY, Federal Defenders of New York, Inc., New York, NY, for Appellant David Blaszczak. DANIEL M. SULLIVAN (James M. McGuire, on the brief), Holwell Shuster & Goldberg LLP, New York, NY, Stephen Fishbein, John A. Nathanson, on the brief, Shearman & Sterling LLP, New York, NY, for Appellant Christopher Worrall. Peter Neiman, Wilmer Cutler Pickering Hale and Dore LLP, New York, NY, Lindsay A. Lewis, Joshua L. Dratel, P.C., New York, NY, for Amicus Curiae National Association of Criminal Defense Lawyers. Kendall Turner, O’Melveny & Myers LLP, Washington, D.C., Anton Metlitsky, O’Melveny & Myers, LLP, New York, NY, for Amici Curiae Law Professors Adam C. Pritchard, Matthew C. Turk, Andrew N. Vollmer, Karen Woody. RICHARD J. SULLIVAN, Circuit Judge:

These consolidated appeals require us to consider whether the federal wire

fraud, securities fraud, and conversion statutes, codified at 18 U.S.C. §§ 1343, 1348,

and 641, respectively, reach misappropriation of a government agency’s

confidential nonpublic information relating to its contemplated rules. Defendants

David Blaszczak, Theodore Huber, Robert Olan, and Christopher Worrall were

3 charged with violating these statutes – and with engaging in securities fraud in

violation of Section 10(b) of the Securities and Exchange Act, 15 U.S.C. § 78j(b), and

SEC Rule 10b-5 (“Title 15 securities fraud”) – by misappropriating confidential

nonpublic information from the Centers for Medicare & Medicaid Services

(“CMS”). The indictment principally alleged that CMS employees, including

Worrall, disclosed the agency’s confidential information to Blaszczak, a “political

intelligence” consultant for hedge funds, who in turn tipped the information to

Huber and Olan, employees of the healthcare-focused hedge fund Deerfield

Management Company, L.P. (“Deerfield”), which traded on it. After a one-month

trial before the United States District Court for the Southern District of New York

(Kaplan, J.), a jury found Defendants guilty of wire fraud, conversion, and, with

the exception of Worrall, Title 18 securities fraud and conspiracy. The jury

acquitted Defendants on all counts alleging Title 15 securities fraud.

Defendants now challenge their convictions on various grounds. For the

reasons set forth below, we reject these challenges. In doing so, we hold, inter alia,

that (1) confidential government information such as the CMS information at issue

here may constitute “property” in the hands of the government for purposes of

the wire fraud and Title 18 securities fraud statutes, and (2) the “personal-benefit”

4 test established in Dirks v. SEC, 463 U.S. 646 (1983), does not apply to these Title

18 fraud statutes. Because we also discern no prejudicial error with respect to the

remaining issues raised on appeal, we affirm the judgments of the district court.

I. BACKGROUND

A. Facts

The jury returned guilty verdicts on counts charging two insider-trading

schemes: (1) a scheme relating to Deerfield that involved all defendants to varying

degrees, and (2) a scheme relating to another hedge fund investment manager,

Visium Asset Management, L.P. (“Visium”), that involved Blaszczak only. We

recite the facts pertaining to each of these schemes in turn, construing the evidence

at trial underlying the counts of conviction in the light most favorable to the

prosecution. See United States v. Kirk Tang Yuk, 885 F.3d 57, 65 (2d Cir. 2018).

1. The Deerfield Scheme

At various times between 2009 and 2014, Olan, Huber, and fellow Deerfield

partner Jordan Fogel – a cooperating witness who pleaded guilty and testified at

trial – approached Blaszczak for the purpose of obtaining so-called

“predecisional” information concerning CMS’s contemplated rules and

regulations. The three Deerfield partners knew that Blaszczak, who had worked

5 at CMS before becoming a consultant for hedge funds, enjoyed unique access to

the agency’s predecisional information through his inside sources at the agency.

Because other consultants did not have access to Blaszczak’s sources, the Deerfield

partners counted him as a particularly lucrative fount of illegal market “edge.”

App’x at 567, 606.

This illegal market edge first paid off for the three Deerfield partners in July

2009, after Blaszczak passed them nonpublic CMS information concerning both

the timing and substance of an upcoming proposed CMS rule change that would

reduce the reimbursement rate for certain radiation oncology treatments. The

Deerfield partners sought to maximize this market edge by trading while “the

information wasn’t known to others, and . . . wasn’t public.” Id. at 593. In late

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Blaszczak
56 F.4th 230 (Second Circuit, 2022)
United States v. Martinez
Air Force Court of Criminal Appeals, 2022
United States v. Radin
Second Circuit, 2020
United States v. Sushovan Hussain
972 F.3d 1138 (Ninth Circuit, 2020)
United States v. Bramer
956 F.3d 91 (Second Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
947 F.3d 19, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-blaszczak-ca2-2019.